Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
84 Alzheimer's Disease Trials near San Antonio, TX
Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerCholine for Alzheimer's Disease
Houston, Texas
This trial tests if choline bitartrate, a dietary supplement, can help people at risk of Alzheimer's Disease. The supplement aims to improve how brain cells handle fats, potentially keeping them healthy and functioning properly.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:55 - 80
Key Eligibility Criteria
Disqualifiers:TBI, Parkinson's, Cardiac Disease, Others
14 Participants Needed
Glycine + N-acetylcysteine for Alzheimer's Disease
Houston, Texas
This trial is testing a supplement called GlyNAC in patients with Alzheimer's disease. The goal is to see if GlyNAC can improve brain function by boosting a natural antioxidant that protects brain cells. Patients are selected based on specific brain scan results and cognitive tests.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, Brain Tumor, Heart Failure, Others
Must Not Be Taking:Insulin
52 Participants Needed
Care Coordination System for Dementia
Houston, Texas
Dementia, a chronic disease of aging, is characterized by progressive cognitive decline that interferes with independent functioning. The medical, psychological, social and functional sequelae of dementia cause great stress to patients, their caregivers, and their family. The investigator proposes to examine effectivness of a home-based care coordination and management device, called Care4AD to help caregivers effectively coordinate, manage, and improve dementia care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:65+
Key Eligibility Criteria
Disqualifiers:Severe Dementia, Major Impairment, Others
100 Participants Needed
Brain Stimulation for Alzheimer's Disease
Houston, Texas
The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explore whether the combined treatment shows promise for reducing neuropsychiatric symptoms like mood swings, apathy, and agitation, and will evaluate the impact of the treatment on caregivers.
The main questions the study aims to answer are:
1. Is the combined brain stimulation treatment practical and well-tolerated?
2. Do preliminary results suggest that this treatment could help manage neuropsychiatric symptoms and support a larger study?
Participants will:
* Attend nine in-person visits over three months.
* Complete one week of in-clinic brain stimulation sessions (iTBS) followed by four weeks of daily at-home brain stimulation sessions (tDCS).
* Take part in brain scans, questionnaires, and brain activity tests before and after the treatment.
This pilot study is a first step to assess whether this combined treatment approach is practical and whether it has potential to improve symptoms, laying the groundwork for larger studies in the future.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 85
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Severe Cardiovascular Disease, Stroke, Others
20 Participants Needed
JNJ-63733657 for Alzheimer's Disease
Houston, Texas
This trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 80
Key Eligibility Criteria
Disqualifiers:MCI, Parkinson's, Alcohol Abuse, Others
Must Be Taking:AD Treatments
523 Participants Needed
Tau Tracer Comparison for Alzheimer's Disease
Houston, Texas
This trial uses special imaging agents to help visualize harmful brain proteins in people at risk of Alzheimer's disease. The agents make these proteins glow during scans, allowing doctors to see them clearly and monitor the disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Pregnant, Breastfeeding, Cognitive Impairment, Others
822 Participants Needed
AVP-786 for Agitation in Alzheimer's Disease
The Woodlands, Texas
This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Non-Alzheimer's Dementia, Unstable Systemic Diseases, Myasthenia Gravis, Others
183 Participants Needed
Stem Cell Therapy for Alzheimer's Disease
Houston, Texas
The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are:
* Does stem cell therapy reduce inflammation in the brain?
* Does stem cell therapy improve brain activity?
* Does stem cell therapy slow down progression to Alzheimer's disease?
Participants will:
* Have a small fat biopsy taken at a doctor's office to process stem cells
* Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks
* Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:60 - 80
Key Eligibility Criteria
Disqualifiers:TBI, Parkinson's, Multiple Sclerosis, Others
12 Participants Needed
Benfotiamine for Alzheimer's Disease
Fort Worth, Texas
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 89
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Diabetes, Cancer, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
406 Participants Needed
Disease-Modifying Drugs for Alzheimer's Disease
Arlington, Texas
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Alcohol/drug Dependence, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, Monoclonal Antibodies
490 Participants Needed
Transcranial Photobiomodulation for Cognitive Decline
Arlington, Texas
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Brain Injuries, Epilepsy, Pacemakers, Others
100 Participants Needed
Goode Health Beverage for Overall Health
Arlington, Texas
The overall research objective of this proposal is to determine the acute and chronic impact of daily supplementation of a Good Health beverage on indices of physiological and neurocognitive health.
Trial Details
Trial Status:Recruiting
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Food Allergy, Pregnant, Breastfeeding, Others
40 Participants Needed
Trontinemab for Alzheimer's Disease
Dallas, Texas
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Cerebrovascular Disease, CNS Trauma, Others
800 Participants Needed
E2814 + Lecanemab for Alzheimer's Disease
Dallas, Texas
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 80
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Stroke, Seizures, Others
Must Be Taking:Acetylcholinesterase Inhibitors
105 Participants Needed
PMN310 for Alzheimer's Disease
Dallas, Texas
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Key Eligibility Criteria
Disqualifiers:Parkinson's, Huntington's, Stroke, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
128 Participants Needed
ExAblate BBB Disruption for Alzheimer's Disease
Dallas, Texas
This trial is testing a device that uses ultrasound waves to temporarily open the brain's protective barrier in patients with Alzheimer's Disease. The goal is to see if this can help medications reach the brain better. Focused ultrasound with microbubbles has been studied recently and shows promise for opening the brain's protective barrier in Alzheimer's disease treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Depression, Seizure, Others
Must Be Taking:Alzheimer's Medications
150 Participants Needed
Remternetug for Alzheimer's Disease
Dallas, Texas
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug.
Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).
Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Neurologic, Psychiatric, Stroke, Substance Use, Others
Must Not Be Taking:Anticoagulants, Immunosuppressives, Chemotherapeutics, Others
280 Participants Needed
Gantenerumab for Alzheimer's Disease
Dallas, Texas
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Neurologic Disease, Psychiatric Disease, Stroke, Alcohol Use, Others
Must Not Be Taking:Immunosuppressives, Anticoagulants
280 Participants Needed
MK-1167 for Alzheimer's Disease
Dallas, Texas
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
* About the safety of MK-1167 and if people tolerate it
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Stroke, CNS Disease, Seizures, Others
Must Be Taking:Acetylcholinesterase Inhibitors
350 Participants Needed
CBD + THC for Agitation in Dementia
Dallas, Texas
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks.
This study will enroll approximately 120 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo.
The double-blind period of this study is 12 weeks. A 12 week optional open-label extension will be offered to participants who complete the double-blind period.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Cannabinoid Allergy, Investigational Drugs, Others
Must Not Be Taking:Cannabinoids
120 Participants Needed
Why Other Patients Applied
"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."
WU
Healthy Volunteer PatientAge: 76
"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."
OF
Alzheimer's Disease PatientAge: 65
"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."
EK
Mild Cognitive Impairment PatientAge: 72
"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."
AH
Dementia PatientAge: 64
"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."
VL
Alzheimer's PatientAge: 71
Intensive Blood Pressure Management for Dementia
Dallas, Texas
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, Dementia, Depression, Heart Disease, Diabetes, Others
Must Be Taking:Antihypertensives
180 Participants Needed
AXS-05 for Alzheimer's Disease Agitation
Mesquite, Texas
The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:65 - 90
Key Eligibility Criteria
Disqualifiers:Hospitalized, Nursing Home, Living Alone, Others
150 Participants Needed
NMRA-323511 for Agitation in Alzheimer's Disease
Mesquite, Texas
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.
Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Epilepsy, Suicidal, Neurologic Disorder, Others
Must Not Be Taking:Anticonvulsants
96 Participants Needed
This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Neurologic, Psychiatric, Substance Use, Others
Must Not Be Taking:Anticoagulants, Monoclonal Antibodies
197 Participants Needed
Know someone looking for new options?
Spread the word